New Leaf Venture Partners, L.L.C.
New York, NY
$43m in 7 US stocks at the end of 30 September 2025. The top 10 are 100.0% of the money. It changed about 36.8% of the portfolio this quarter.
Value
$43m
Stocks
7
Top 10 share
100.0%
Turnover
36.8%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- Passage BIOPASG1.6% of the fund-97%
Sold out
Sold their entire stake.
- Iterum TherapeuticsITRMF-100%
Holdings
- Crinetics PharmaceuticalsCRNX
- Share
- 13.6%
- Value
- $6m
- Shares
- 141,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Edgewise TherapeuticsEWTX | 38.8% | $17m | 1,030,161 | Held |
| ArvinasARVN | 31.4% | $14m | 1,585,721 | Held |
| Crinetics PharmaceuticalsCRNX | 13.6% | $6m | 141,000 | Held |
| Cogent BiosciencesCOGT | 8.4% | $4m | 250,765 | Held |
| RallybioRLYB | 3.8% | $2m | 3,301,603 | Held |
| AlectorALEC | 2.3% | $1m | 339,569 | Held |
| Passage BIOPASG | 1.6% | $702,031 | 87,426 | -97% |
Over time and by industry
Value over time
Sep '25
Value is down 18.7% since 30 June 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.